Zephyr AI: Rachel Brake

Precision medicine technology company Zephyr AI has appointed Rachael Brake as its CSO. Brake is the former CSO at Corbus Pharmaceuticals. Prior to this, she spent 11 years at Takeda Oncology, most recently as head of US medical affairs, oncology, and earlier as global program VP and associate director in translational research. Brake began her career as a research scientist at the Western Australian Institute for Medical Research before moving to Amgen in the US where she worked as a principal scientist. She holds a bachelor of science degree in molecular biology and biochemistry from the Australian National University and a PhD from the University of Western Australia.